MADRID — Semaglutide (Wegovy) prevents major cardiac events including death in adults with overweight/obesity and cardiovascular disease (CVD), both with and without impaired kidney function ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

Around one in seven Medicare beneficiaries with a high body mass index (BMI) may be newly eligible for semaglutide treatment after Medicare allowed Part D plans to cover the drug for patients with ...

According to a study published today in Annals of Internal Medicine, expanding Medicare coverage for semaglutide could make millions of older Americans newly eligible for the drug, but with the ...

A new study finds a significant correlation between the use of semaglutide drugs such as Ozempic, antidepressant, or benzodiazepine use, and suicidal ideation. No such link was found between ...

A study published in JAMA Internal Medicine finds semaglutide, a weight loss medication, does not increase depressive symptoms or suicidal behavior in individuals without known mental health disorders ...

Studies found that semaglutide reduced inflammation regardless of whether users lost weight, The Times of London reported. Weight-loss drugs such as Ozempic come with a risk of severe side effects.

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. Tirzepatide is less expensive and may be more effective. However, the drug is still new, and more research is needed.

These two injected drugs are versions of semaglutide. In multiple new data analyses, the drugs appeared to cut people's odds for heart failure and its complications, reduce deaths from COVID-19 ...

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without ...